This website is intended for healthcare professionals only

Trending Topic

Close-up of a person rubbing their temple, depicting persistent headache pain
13 mins

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked

Migraines profoundly impact well-being, especially in children and adolescents. From 1990 to 2021, global pediatric migraine disability has increased, with particular vulnerability in females and adolescents aged 15–19.1 A 2023 meta-analysis found the prevalence of primary headache diagnosis in individuals aged 8–18 years to be 62%.2 The prevalence of a migraine diagnosis was 11%; 8% […]

James E Galvin, AAIC 2021: Aducanumab for the Treatment of Alzheimer’s Disease

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Published Online: Sep 21st 2021

touchNEUROLOGY joins Prof James Galvin (University of Miami Miller School of Medicine, Miami, FL, USA) to discuss aducanumab for the treatment of Alzheimer’s disease, and what this recent accelerated approval might mean for future potential treatments.

Questions
1. Why has the recent FDA accelerated approval of aducanumab for Alzheimer’s disease been so controversial? (00:13-02:00)
2. Why did the EMERGE clinical study meet its primary endpoint, but the ENGAGE study did not? (02:00-04:21)
3. Which patients are most likely to benefit from aducanumab and in whom should it not be used? (04:21-05:13)
4. What are the consequences of this accelerated approval and how will this impact future research for Alzheimer’s disease? (05:13-08:38)

Disclosures: Prof Galvin has no financial or non-financial conflicts of interest to declare in relation to this video.

Support: Interview and filming supported by Touch Medical Media. Interview conducted by Sophie Nickelson.

Filmed in coverage of the 2021 AAIC Annual Meeting.

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Close Popup